Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.95
Bid: 2.90
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.10 (3.448%)
Open: 2.95
High: 2.95
Low: 2.95
Prev. Close: 2.95
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shareholder Communications

17 Aug 2022 07:00

RNS Number : 2408W
ValiRx PLC
17 August 2022
 

17 August 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Shareholder Communications

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce the appointment of strategic marketing and PR agency, V Formation Limited and the appointment of Dr Adam Hargreaves as a shareholder representative. The appointments represent the Company's continued strategy to improve and enhance communications with its shareholders.

V Formation Limited is a Nottingham-based public relations and marketing communications agency that specialises in supporting clients in the life sciences sector, ensuring that news and corporate development updates are optimised and communicated in a clear, transparent and precise manner. V Formation will liaise closely with Dr Hargreaves in his role as shareholder representative, as well as with ValiRx's Nominated Adviser and brokers, to improve the interpretation and dissemination of Company newsflow following publication via a regulatory information provider.

Dr Adam Hargreaves has agreed to become a shareholder representative to help improve communications between the Company and shareholders. The Company's overall policy on shareholder communications is unchanged, with written quarterly updates and quarterly live Q&A events continuing. However, shareholders can additionally communicate with Dr Hargreaves directly to seek clarification of any details that have been publicly announced, or through a shareholder community. Dr Hargreaves will have regular interaction with the Company to ensure that shareholders' views are fully represented to the Board. Shareholders wishing to communicate directly with Board members are welcome to do so, with a prompt response when possible.

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

 

Dr Suzanne Dilly, CEO

 

Dr Adam Hargreaves, Shareholder Representative

 

Tel: +44 (0) 2476 796496

www.valirx.com

Suzanne.Dilly@valirx.com

 

Adam.Hargreaves@pathcelerate.com

V Formation (Public Relations)

 

Lucy Wharton - Senior PR Executive

Sue Carr - Director

 

 

Contact details

www.vformation.biz

lucy@vformation.biz

sue@vformation.biz

+44 (0)115 787 0206

Cairn Financial Advisers LLP (Nominated Adviser)

 

Liam Murray/Jo Turner/Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 088

Cenkos Securities Limited (Joint Broker)

 

Russell Kerr/Michael Johnson (Sales)

 

Callum Davidson/Giles Balleny (Corporate Finance)

Tel: +44 (0) 20 7397 8900

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker  

Tel: +44 (0) 20 3657 0050

 

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

About V Formation

V Formation is an established marketing and PR agency based at BioCity Nottingham. The team of experienced marketing and PR consultants deliver inspiring, insightful and supportive marketing advice, strategy and tactics to take businesses closer to their clients and help them find their competitive edge. 

 

V Formation works with ambitious SMEs in the life sciences and high-tech sectors, professional services firms and family businesses. It provides in-house marketing and support, guidance on strategic direction and assistance with tactical marketing and PR. The company's directors are Sue Carr and Hilary Campton.

 

For more information: www.vformation.biz or 0115 822 6364 

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDIISBDGDL
Date   Source Headline
31st May 20117:00 amRNSTotal Voting Rights
26th May 20112:56 pmRNSHolding(s) in Company
20th May 20117:00 amRNSWebsite update
14th Apr 20117:00 amRNSAgreements with Imperial College & Oxford Uni
9th Mar 20112:54 pmRNSHolding(s) in Company
9th Mar 201111:15 amRNSHolding(s) in Company
7th Mar 201110:56 amRNSResult of EGM
7th Mar 20117:00 amRNSStatement re General Meeting
25th Feb 20112:09 pmRNSWebsite Update
18th Feb 20112:54 pmRNSPublication of Circular and Notice of GM
16th Feb 20117:19 amRNSIssue of Equity
14th Feb 20117:00 amRNSUpdate
1st Feb 201111:38 amRNSTotal Voting Rights
31st Jan 20117:00 amRNSFurther re Sale of Belgian Subsidiary, ValiBIO SA
27th Jan 20117:00 amRNSIssue of Equity
26th Jan 201110:58 amRNSResult of General Meeting
11th Jan 20117:00 amRNSPublication of Circular and Notice of GM
2nd Dec 20107:00 amRNSUpdate - Eurostars Programme
1st Dec 20107:00 amRNSTotal Voting Rights
10th Nov 20107:00 amRNSIssue of equity and update
1st Nov 20104:12 pmRNSTotal Voting Rights
29th Oct 20103:16 pmRNSIssue of Equity
29th Oct 20103:15 pmRNSChange of Adviser
11th Oct 201010:51 amRNSCompletion of Disposal
30th Sep 20102:17 pmRNSHalf Yearly Report
23rd Sep 20107:00 amRNSDisposal
31st Aug 20107:00 amRNSTotal Voting Rights
16th Aug 20105:12 pmRNSIssue of Equity
12th Aug 20107:00 amRNSLicensing Deal with Cancer Research Technology
15th Jul 20107:00 amRNSHPV Test Starts Clinical Validation
30th Jun 201010:15 amRNSResult of AGM
17th Jun 20107:00 amRNSEurostars' GeneICE Programme - First Year Review
17th Jun 20107:00 amRNSGeneICE Update
24th May 20107:00 amRNSRe Agreement
30th Apr 20102:47 pmRNSTotal Voting Rights
21st Apr 20104:08 pmRNSIssue of Equity - Replacement
21st Apr 20103:14 pmRNSResult of General Meeting
1st Apr 20103:19 pmRNSProposed reorg of share capital & Gen Meeting
1st Apr 201010:06 amRNSIssue of Equity
1st Apr 201010:06 amRNSTrading Update
31st Mar 20107:00 amRNSTotal Voting Rights
17th Mar 20107:00 amRNSSales and Distribution Agreement
15th Mar 201011:07 amRNSValiRx announces good stability data for VAL201
9th Mar 20107:00 amRNSFunding and Partnership Agreement
5th Mar 20103:00 pmRNSIssue of Equity
26th Feb 20104:30 pmRNSTotal Voting Rights
16th Feb 20109:00 amRNSIssue of Equity
29th Jan 201010:10 amRNSTotal Voting Rights
19th Jan 20107:00 amRNSGeneICE Update
13th Jan 20107:56 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.